# Medical Animation Market

> Medical animation market: USD 780 million in 2025, rising 8.90% a year to USD 1.83 billion by 2035 as drug launches, device innovation and medical education add projects.

Publisher: Douglas Insights  
Author: Douglas Insights Research Desk  
Report code: DI-HC-10878  
Published: 2026-11-06  
Last updated: 2026-11-06  
Next review: May 2027  
Page: https://www.douglasinsights.com/medical-animation-market/

## Key figures

| Measure | Value | How it is built |
| --- | --- | --- |
| Market size · 2025 | $780 Mn | About 52,000 projects and licences x USD 15,000 = USD 780 million. |
| Forecast · 2035 | $1.83 Bn | Base case: 10.0% projects and minus 1.0% value per project a year. |
| Revenue CAGR · 2026–2035 | 8.90% | (1.100 x 0.990) minus 1. |
| Volume · 2035 | About 134,900 projects and licences | Drug launches, device innovation, medical education and patient information, less AI substitutes, scarce animators and ad-rule uncertainty. |
| Leading segment | Pharma and biotech mechanism-of-action, 38.0% | USD 296 million to USD 670 million. |
| Fastest segment | Medical education and 3D anatomy platforms, 10.0% | USD 140 million to USD 364 million. |
| Leading region | North America, 48.0% | Most global drug and device launches start in the United States. |
| Market leader | Elsevier (Complete Anatomy), about 6% (estimate) | Douglas Insights estimate; Elsevier about 6%, Nucleus Medical Media 4%; top five 19%. |
| Event | 47 novel drugs by October 2026 | FDA approved 47 novel drugs by 20 October 2026, against 46 in all of 2025. |

## Key takeaways

- The medical animation market is worth USD 780 million in 2025 and USD 1.83 billion in 2035, an 8.90% CAGR.
- About 52,000 paid projects and licences at an average USD 15,000 form the 2025 base; projects grow 10.0% a year while value per project falls 1.0%.
- Pharma and biotech mechanism-of-action work holds 38.0% of value; education and 3D anatomy platforms grow fastest at 10.0%.
- North America buys 48.0% of value; Asia Pacific grows fastest at 11.5%.
- Launch demand per 1,000 US animators rises about 9% in 2026, the Launch Animation Pipeline Index shows, as FDA approvals outpace a flat animator workforce.

The US Food and Drug Administration (FDA) approved 46 novel drugs in 2025, its [Novel Drug Approvals for 2025](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025) page shows, and 47 more by 20 October 2026, its [2026 list](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026) shows; each launch needs a mechanism-of-action film for doctors, patients and sales teams. The medical animation market covers commissioned 2D and 3D animation, interactive and extended reality (XR) visualisation and licensed 3D anatomy libraries made to explain drugs, devices, procedures and the human body, valued at what pharmaceutical, device, education, healthcare and legal clients pay studios and platforms. General video production, advertising media buying, surgical simulators sold as hardware and in-house staff costs are excluded. Douglas Insights sizes the market at USD 780 million in 2025, about 52,000 paid projects and platform licences at an average USD 15,000, and at USD 1.83 billion in 2035, an 8.90% compound annual growth rate (CAGR). The study sits beside our [Visual Effects Market](https://www.douglasinsights.com/visual-effects-market/), [Military Training and Simulation Systems Market](https://www.douglasinsights.com/military-training-and-simulation-systems-market/) and [U.S. Pharmaceutical Drug Market](https://www.douglasinsights.com/u-s-pharmaceutical-drug-market/) reports; every figure follows the Douglas Insights [research methodology](https://www.douglasinsights.com/research-methodology/).

## Which medical animation applications earn the most: drug mechanism films, device animation, education platforms or patient content?

Pharmaceutical and biotech mechanism-of-action work earns the most, 38.0% of 2025 value or USD 296 million, Douglas Insights estimates. Device animation takes 22.0%, education and 3D anatomy platforms 18.0%, patient education 14.0% and legal and other uses 8.0%.

| Application | Share 2025 | Value 2025 | CAGR 2026-2035 | Value 2035 |
| --- | --- | --- | --- | --- |
| Pharma and biotech mechanism-of-action | 38.0% | USD 296 million | 8.5% | USD 670 million |
| Medical device marketing and training | 22.0% | USD 172 million | 9.5% | USD 425 million |
| Medical education and 3D anatomy platforms | 18.0% | USD 140 million | 10.0% | USD 364 million |
| Patient education | 14.0% | USD 109 million | 9.0% | USD 259 million |
| Legal and other | 8.0% | USD 62.4 million | 5.0% | USD 102 million |

Mechanism-of-action films lead because every new medicine has to show doctors how a molecule binds, blocks or edits its target, and those films are reused in congress booths, sales detailing, websites and investor decks. Douglas Insights estimates about 15,000 pharma and biotech projects in 2025 at an average USD 19,800, from short 2D explainers near USD 5,000 to full 3D launch films above USD 80,000. Value grows 8.5% a year to USD 670 million by 2035 as gene, cell and antibody-drug conjugate therapies, which are harder to explain than tablets, form a larger share of launches.

Device animation, USD 172 million, grows 9.5% to USD 425 million because surgeons and hospital buyers must see how an implant, catheter or robot works inside the body before they adopt it. Education and 3D anatomy platforms, USD 140 million, grow fastest at 10.0% to USD 364 million as medical schools and nursing programmes license interactive anatomy instead of buying atlases. Patient education, USD 109 million, grows 9.0% as hospitals put procedure videos on portals. Legal animation for courtroom injury cases, USD 62.4 million, grows 5.0%. Application values for 2035 sum to USD 1.82 billion, 0.5% below the headline.

## Which animation formats and clients buy most: 3D films, 2D explainers or interactive and XR content?

Rendered 3D film takes about 58% of 2025 value, Douglas Insights estimates, 2D and motion graphics about 24% and interactive, augmented reality and virtual reality content about 18%. Life-science companies commission about 60% of value.

Rendered 3D dominates because molecular and surgical scenes need accurate depth, lighting and tissue texture that 2D cannot show. Douglas Insights estimates an average 3D project at about USD 22,000 against about USD 7,500 for a 2D explainer. Interactive and XR content is the fastest-growing format: the FDA's [list of augmented reality and virtual reality medical devices](https://www.fda.gov/medical-devices/digital-health-center-excellence/augmented-reality-and-virtual-reality-medical-devices), current as of 4 September 2026, has 120 entries, the latest the Helion Viewer Suite cleared on 27 May 2026, and each such device needs 3D assets built to clinical accuracy.

Clients split into four groups. Drug, biotech and device companies and their agencies buy about 60% of value, universities and education publishers about 18%, and hospitals, insurers and law firms about 22%, Douglas Insights estimates. Apple listed 16 health apps for Vision Pro, including Elsevier's Complete HeartX, Stryker's myMako and Siemens Healthineers' Cinematic Reality, in its [release of 11 March 2024](https://www.apple.com/newsroom/2024/03/apple-vision-pro-unlocks-new-opportunities-for-health-app-developers/), showing how device and publishing clients move animation into spatial formats.

## What drives medical animation demand: drug launches, device innovation, medical education or patient information?

Paid projects and licences rise 10.00% a year in our base case, from about 52,000 in 2025 to 134,900 in 2035. Four drivers add 11.60 gross points; restraints remove 1.60.

### Drug launches and pipeline communication: 3.40 points

New medicines are the largest driver, worth 3.40 points. The FDA's drug centre approved 46 novel drugs in 2025, its [2025 approvals page](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025) states, and 47 between January and 20 October 2026, when it approved Hibsago (bepirovirsen), the [2026 page](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026) shows. Members of PhRMA, the US industry body, invested more than USD 110 billion in research and development in 2025, its [investment update](https://phrma.org/blog/icymi-biopharmaceutical-companies-in-america-hit-new-investment-milestone) states. Douglas Insights estimates that each approved drug generates 8 to 12 animation projects across congress, sales and patient channels in its first two years, and that late-stage pipeline assets add about 4,000 projects a year.

### Device innovation: 2.80 points

Device launches add 2.80 points. The FDA's device centre authorised 124 novel devices in 2025, gave marketing authorisation to 44 breakthrough devices and received 21,780 submissions, its [CDRH Annual Report 2025](https://www.fda.gov/media/190779/download), posted on 28 January 2026, shows; it has now authorised more than 1,300 AI-enabled devices. Douglas Insights estimates that a novel device commissions about 6 animation projects for surgeon training, sales and regulatory submissions, worth about USD 25,000 each.

### Medical education and 3D anatomy: 3.00 points

Education adds 3.00 points. US medical schools enrolled a record 100,723 students in 2025, the first time above 100,000, with 23,440 matriculants, up 1.2%, and 54,699 applicants, up 5.3%, the Association of American Medical Colleges (AAMC) reported on [9 December 2025](https://www.aamc.org/news/us-medical-schools-enroll-record-number-students-2025). The World Directory of Medical Schools lists more than 4,000 schools worldwide, its [about page](https://www.wdoms.org/about/) states, and Primal Pictures says more than 1,500 academic and clinical institutions in 150 countries use its 3D anatomy, its [company page](https://primalpictures.com/about/) shows. Douglas Insights estimates about 14,000 institutional anatomy licences in 2025, growing 11% a year.

### Patient information: 2.40 points

Patient-facing content adds the last 2.40 points. BioDigital says its 3D human platform supports more than 100 million health conversations a year across more than 8,000 anatomical structures, 600 conditions and 8 languages, its [company page](https://www.biodigital.com/about) states. Douglas Insights estimates about 9,000 patient education projects in 2025 for hospitals, insurers and drugmakers. Summed, 3.40 + 2.80 + 3.00 + 2.40 = 11.60 points; after 1.60 points of restraints the 10.00% project leg combined with the minus 1.00% value-per-project leg gives the 8.90% revenue rate.

## What holds back medical animation: generative AI substitutes, scarce animators or advertising rule uncertainty?

Three restraints remove 1.60 points a year from project growth: generative AI video tools take 0.70 points, a thin pool of trained medical animators 0.50 points and uncertainty over US broadcast advertising rules 0.40 points.

Generative AI is the largest brake. Google launched its Veo 3 video model on 20 May 2025, its [I/O 2025 announcement](https://blog.google/innovation-and-ai/products/generative-media-models-io-2025/) states, and OpenAI released Sora 2 on 30 September 2025, its [launch post](https://openai.com/index/sora-2/) shows. Simple explainers that once went to a studio can now be drafted in-house, Douglas Insights estimates, removing about 1,500 low-end projects a year by 2028. Accuracy limits the loss: OpenAI closed the Sora web and app service on 26 April 2026, its [help centre notice](https://help.openai.com/en/articles/20001152) states, and medical and legal reviewers still reject anatomy that a model invents.

Talent is the second brake. The US Bureau of Labor Statistics counts 51,900 special effects artists and animators in 2025 at a median USD 102,030 a year and projects no growth from 2025 to 2035, its [Occupational Outlook Handbook, updated 29 October 2026](https://www.bls.gov/ooh/arts-and-design/multimedia-artists-and-animators.htm), shows. Only 5 graduate medical illustration programmes in North America hold accreditation, the [Association of Medical Illustrators](https://ami.org/medical-illustration/enter-the-profession/education/graduate-programs/) lists. The third brake is rule uncertainty: drugmakers waiting for the FDA's planned change to broadcast advertising rules may delay some consumer campaigns, Douglas Insights estimates.

## Which region buys the most medical animation, and where does demand grow fastest?

North America buys the most, about USD 374 million or 48.0% of 2025 value, led by the United States. Asia Pacific grows fastest at 11.5% a year, reaching USD 394 million by 2035.

| Region | Value 2025 | Share 2025 | Value 2026 | CAGR 2026-2035 | Value 2035 |
| --- | --- | --- | --- | --- | --- |
| North America | USD 374 million | 48.0% | USD 405 million | 8.2% | USD 823 million |
| Europe | USD 211 million | 27.0% | USD 229 million | 8.5% | USD 476 million |
| Asia Pacific | USD 133 million | 17.0% | USD 148 million | 11.5% | USD 394 million |
| Latin America | USD 31.2 million | 4.0% | USD 34.2 million | 9.5% | USD 77.3 million |
| Middle East and Africa | USD 31.2 million | 4.0% | USD 34.5 million | 10.5% | USD 84.7 million |

North America leads because most global drug and device launches start in the United States and because the country allows prescription drug advertising to consumers. AbbVie alone reported advertising expenses of USD 2.1 billion in 2025, the same as in 2024, its [Form 10-K for 2025](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm) shows. Douglas Insights estimates about 23,000 North American projects in 2025 at an average USD 16,300.

Europe, USD 211 million, grows 8.5%, with studios in the United Kingdom, Germany and Switzerland serving drugmakers' medical affairs and congress teams rather than consumer advertising. Asia Pacific, USD 133 million, grows 11.5% as Chinese, Japanese, Korean and Indian drug and device companies take more products global; India and the Philippines also host production teams that work for Western studios. Latin America and the Middle East and Africa, USD 31.2 million each, grow from small bases, led by hospital patient education and medical school licences. Regional values sum to USD 850 million in 2026, matching the headline, and USD 1.86 billion in 2035, 1.4% above it.

## Which companies lead medical animation, and why is the field so fragmented?

Elsevier, through Complete Anatomy, leads with about 6% of 2025 value, a Douglas Insights estimate, ahead of Nucleus Medical Media at 4% and Visible Body, Random42 and BioDigital at 3% each. The top five hold 19%.

| Company | Base and offer | Latest public figure | Estimated share 2025 |
| --- | --- | --- | --- |
| Elsevier (RELX) | Amsterdam and London; Complete Anatomy, 3D4Medical | RELX STM revenue GBP 2.71 billion, 2025 | 6% |
| Nucleus Medical Media | Kennesaw, Georgia; animation studio and library | Founded 1997 | 4% |
| Visible Body | Newton, Massachusetts; 3D anatomy apps | Private | 3% |
| Random42 (Lockwood Group) | London; pharma mechanism films | Sold to Lockwood, 20 June 2022 | 3% |
| BioDigital | New York; 3D human platform | 100 million conversations a year | 3% |
| Primal Pictures (Citeline) | London; 3D anatomy | 1,500 institutions, 150 countries | 2% |

Elsevier's parent RELX grew its scientific, technical and medical segment 5% on an underlying basis to GBP 2.71 billion in 2025, its [results of 12 February 2026](https://www.relx.com/~/media/Files/R/RELX-Group/documents/press-releases/2026/results-2025-pressrelease.pdf) show; Complete Anatomy is a small part of that line. Wolters Kluwer's Health division grew 5% organically to EUR 1.60 billion, with its learning, research and practice unit up 3%, its [2025 results of 25 February 2026](https://assets.contenthub.wolterskluwer.com/api/public/content/3118646-2026-02-25-wolters-kluwer-2025-full-year-results-7391945524?v=2c966da9) show. Nucleus Medical Media, founded in 1997, calls itself the largest employer of graduate-degreed medical animators, illustrators and writers, its [company page](https://www.nucleusmedicalmedia.com/who-we-are) states.

The field is fragmented because most work is bespoke. Graphite Capital sold Random42 to The Lockwood Group, a US healthcare communications group, on 20 June 2022, its [announcement](https://www.graphitecapital.com/news/graphite-capital-sells-random42-to-the-lockwood-group) states, a sign that agency groups buy studios to offer animation inside wider launch contracts. XVIVO, Ghost Productions, Infuse Medical, Hybrid Medical Animation and Scientific Animations compete for pharma and device projects; Douglas Insights estimates more than 400 specialist studios worldwide, most with fewer than 30 staff.

## What does medical animation cost per project, and why does value per project fall?

A medical animation project or licence earns an average USD 15,000 in 2025, Douglas Insights estimates, from about USD 1,500 for an anatomy seat bundle to more than USD 80,000 for a 3D launch film. Value falls 1.00% a year.

The average drops to about USD 13,600 by 2035, a Douglas Insights estimate, because cheaper tools and AI-assisted steps cut studio hours per minute of finished film. Software is no longer the barrier: Adobe charges USD 69.99 a month for Creative Cloud Pro in the United States, its [plan page updated 12 February 2026](https://helpx.adobe.com/account/individual/subscriptions-and-plans/plan-types-and-eligibility/changes-to-individual-plan.html) shows; Autodesk's Maya Indie costs USD 330 a year for creators earning under USD 100,000, its [blog of 26 October 2026](https://blogs.autodesk.com/media-and-entertainment/2026/10/26/autodesk-maya-vs-maya-creative-vs-maya-indie-which-one-is-best-for-you/) states; and Unreal Engine costs USD 1,850 a seat a year for non-game users, Epic's [licensing page](https://www.unrealengine.com/license) states.

Machine video sets a new reference cost. Google cut the Veo 3 programming interface price to USD 0.40 a second from USD 0.75 on 8 September 2025, and Veo 3 Fast to USD 0.15 from USD 0.40, its [developer blog](https://developers.googleblog.com/veo-3-and-veo-3-fast-new-pricing-new-configurations-and-better-resolution/) shows, so a 90-second raw clip costs USD 36. Labour remains most of a studio bill: a median animator earns USD 49.06 an hour, the [BLS handbook](https://www.bls.gov/ooh/arts-and-design/multimedia-artists-and-animators.htm) shows, and a 3D launch film still takes 300 to 600 skilled hours, Douglas Insights estimates, because scientific review and regulatory checks cannot be automated.

## Which rules shape medical animation, from FDA advertising standards to EU AI labelling?

Three kinds of rules shape the market: US rules on how prescription drug ads present risks, European limits on advertising medicines to the public, and new transparency duties for AI-generated video.

US advertising standards come first. The FDA's final rule requiring the major statement of risks in television and radio drug ads to be presented in a "clear, conspicuous and neutral" manner was published on 21 November 2023, took effect on 20 May 2024 and required compliance from 20 November 2024, the [Federal Register](https://www.govinfo.gov/content/pkg/FR-2023-11-21/pdf/2023-25428.pdf) shows. On 9 September 2025 the FDA said it was sending thousands of letters and about 100 cease-and-desist letters over misleading drug ads and starting rulemaking to close the 1997 "adequate provision" loophole, its [announcement](https://www.fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising) states; the same day the Department of Health and Human Services said patients who ask for an advertised drug are about 17 times more likely to get it, its [release](https://www.hhs.gov/press-room/hhs-fda-drug-ad-transparency.html) shows. The proposed rule appears in the 2026 regulatory agenda, law firm Foley Hoag noted on [7 July 2026](https://www.foleyhoag.com/news-and-insights/publications/alerts-and-updates/2026/july/fda-proposes-to-eliminate-adequate-provision-for-broadcast-prescription-drug-advertising/). Longer risk disclosures favour animation, which can show a mechanism and its risks in the same seconds.

Europe sets a different floor. Article 88 of [Directive 2001/83/EC](https://eur-lex.europa.eu/eli/dir/2001/83/oj) bans advertising prescription medicines to the general public, so European drug animation goes to doctors, congresses and approved patient information instead of broadcast media. The EU Artificial Intelligence Act, [Regulation (EU) 2024/1689](https://eur-lex.europa.eu/eli/reg/2024/1689/oj), requires those deploying AI-generated or manipulated video to disclose it, with most obligations applying from 2 August 2026; Douglas Insights expects pharma compliance teams to require that any AI-made medical footage be labelled and reviewed, which keeps human studios in the loop.

## What if AI tools substitute faster or XR training scales: how large is medical animation in 2035?

The medical animation market ends 2035 between USD 1.19 billion and USD 2.53 billion across three cases, around a USD 1.83 billion base. Project growth and the pace of AI-driven cost cuts set most of the spread.

| Case | Project leg | Value-per-project leg | Revenue rate | 2035 value |
| --- | --- | --- | --- | --- |
| Slower | 7.00% | -2.50% | 4.33% | USD 1.19 billion |
| Base case | 10.00% | -1.00% | 8.90% | USD 1.83 billion |
| Faster | 12.50% | 0.00% | 12.50% | USD 2.53 billion |

In the slower case generative video replaces most 2D explainers, drug launches slow and US consumer advertising shrinks under new risk rules, taking 3.0 points off the project leg and 1.5 points off value. In the faster case XR surgical training and interactive anatomy scale across medical schools and device makers, adding 2.5 points of projects and holding value flat. One extra point of yearly revenue growth adds about USD 165 million to 2035 value, Douglas Insights estimates.

Public signals bracket the base. RELX's medical and scientific segment grew 5% and Wolters Kluwer Health 5% organically in 2025, while FDA novel drug approvals in 2026 already passed the 2025 total by October; our 8.90% rate sits above the publishers because animation is a growing slice of their spending.

## Douglas Exclusive: the Launch Animation Pipeline Index

The Launch Animation Pipeline Index is a Douglas Insights model built from 9 inputs: 2 drug approval counts, 3 FDA device counts, 2 AAMC enrolment figures, 1 AR and VR device list and 1 BLS workforce count.

| Input | Figure | Source date |
| --- | --- | --- |
| Novel drugs approved, 2025 | 46 | 8 July 2026 |
| Novel drugs approved, 2026 to 20 October | 47 | 20 October 2026 |
| Novel devices authorised, 2025 | 124 | 28 January 2026 |
| Breakthrough devices authorised, 2025 | 44 | 28 January 2026 |
| AI-enabled devices authorised, cumulative | 1,300+ | 28 January 2026 |
| US MD enrolment, 2025 | 100,723 | 9 December 2025 |
| US matriculants, 2025 | 23,440 | 9 December 2025 |
| AR and VR medical devices listed | 120 | 4 September 2026 |
| US animators employed, 2025 | 51,900 | 29 October 2026 |

The finding, a Douglas Insights estimate: 2025's 46 drugs and 124 novel devices created about 1,200 launch animation projects in their first year, and 2026's faster drug pace lifts that to about 1,300, while the US animator workforce is projected flat. Launch demand per 1,000 US animators rises from about 23 projects to about 25, a 9% squeeze that supports studio rates for complex 3D work.

The index changes how to read the next three years. The pressure on price sits in simple 2D content, where AI tools compete, while launch-grade 3D and XR work for new molecules and devices stays scarce. Douglas Insights expects studios with scientific staff and regulatory review processes to hold their margins while generalist video shops lose medical clients.

## How does the methodology turn 52,000 projects into USD 780 million?

Our methodology multiplies about 52,000 paid medical animation projects and platform licences in 2025 by an average USD 15,000 to reach USD 780 million, then grows projects 10.00% and lowers value per project 1.00% a year.

The model covers 5 applications, 3 formats and 5 regions, using 48 data points, 18 sourced and 30 modelled. Project counts come from drug and device approval numbers, institution counts and studio capacity, and values from published tool costs, wage data and studio rate cards; the splits are Douglas Insights estimates. Arithmetic: 15,000 pharma projects x USD 19,800 + 37,000 other projects and licences x USD 13,050 = about USD 780 million; USD 780 million x (1.100 x 0.990)^10 = USD 1.83 billion. Projects reach about 57,200 in 2026 and 134,900 in 2035.

Two cross-checks agree. First, about 5,200 specialist staff across some 400 studios and platforms, each generating about USD 150,000 a year in revenue, would produce the same USD 780 million, Douglas Insights estimates. Second, about 14,000 institutional anatomy licences at an average USD 10,000 a year give the USD 140 million education and platform segment, matching the application split. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our [editorial standards](https://www.douglasinsights.com/research-methodology/) explain.

## What counts in the medical animation study, and what is excluded?

The study counts commissioned medical and scientific animation, interactive and XR medical visualisation and licensed 3D anatomy libraries. General video production, media buying, surgical simulator hardware, in-house salaries and entertainment animation are excluded.

The study splits value by 5 applications, 3 formats and 5 regions: North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Values are in US dollars at 2025 average exchange rates, counted at what the client pays the studio or platform. Readers following wider animation can compare our [Visual Effects Market](https://www.douglasinsights.com/visual-effects-market/) study.

## Market by segment

| Segment | Share | Value |
| --- | --- | --- |
| Pharma and biotech mechanism-of-action | 38% | $296 Mn |
| Medical device marketing and training | 22% | $172 Mn |
| Medical education and 3D anatomy platforms | 18% | $140 Mn |
| Patient education | 14% | $109 Mn |
| Legal and other | 8% | $62.4 Mn |

## Market by region (USD million)

| Region | 2025 | 2026 | 2035 | CAGR 2026-2035 |
| --- | --- | --- | --- | --- |
| Global | 780 | 849.4 | 1,829.7 | 8.9% |
| North America | 374.4 | 405.1 | 823.4 | 8.2% |
| Europe | 210.6 | 228.5 | 476.2 | 8.5% |
| Asia Pacific | 132.6 | 147.9 | 393.8 | 11.5% |
| Latin America | 31.2 | 34.2 | 77.3 | 9.5% |
| Middle East and Africa | 31.2 | 34.5 | 84.7 | 10.5% |

## Dataset

| Series | Value | Unit |
| --- | --- | --- |
| Market size 2025 | 780 | USD million |
| Market size 2035 | 1,829.7 | USD million |
| Revenue CAGR 2026-2035 | 8.9 | percent |
| Volume CAGR 2026-2035 | 10 | percent |
| Value per project CAGR 2026-2035 | -1 | percent |

## Frequently asked questions

### How big is the medical animation market in 2025 and 2035?

USD 780 million in 2025, from about 52,000 paid projects and licences at an average USD 15,000, rising to USD 1.83 billion by 2035 at an 8.90% CAGR.

### Which medical animation application earns the most?

Pharma and biotech mechanism-of-action work, with 38.0% of 2025 value or USD 296 million; medical education and 3D anatomy platforms grow fastest at 10.0% a year.

### Which companies lead medical animation?

Elsevier through Complete Anatomy with about 6% of 2025 value, Nucleus Medical Media with 4% and Visible Body, Random42 and BioDigital with about 3% each, Douglas Insights estimates.

### Which region buys the most medical animation?

North America, with 48.0% of 2025 value or USD 374 million; Asia Pacific grows fastest at 11.5% a year.

### How much does a medical animation cost?

An average USD 15,000 a project or licence in 2025, from about USD 1,500 for an anatomy seat bundle to more than USD 80,000 for a 3D launch film, Douglas Insights estimates.

### Will generative AI replace medical animation studios?

It removes some simple 2D work, worth about 0.70 points of yearly project growth in our model, but medical review, the FDA's risk-presentation rules and EU AI labelling keep launch-grade 3D work with specialist studios.

### How far apart are the slower and faster 2035 cases?

USD 1.19 billion in the slower case and USD 2.53 billion in the faster case, against a USD 1.83 billion base.

## Sources

- [US FDA, Novel Drug Approvals for 2025](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)
- [US FDA, Novel Drug Approvals for 2026](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)
- [US FDA, CDRH Annual Report 2025](https://www.fda.gov/media/190779/download)
- [US FDA, Augmented Reality and Virtual Reality in Medical Devices](https://www.fda.gov/medical-devices/digital-health-center-excellence/augmented-reality-and-virtual-reality-medical-devices)
- [US FDA, FDA launches crackdown on deceptive drug advertising](https://www.fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising)
- [US HHS, HHS, FDA to require full safety disclosures in drug ads](https://www.hhs.gov/press-room/hhs-fda-drug-ad-transparency.html)
- [Federal Register, Direct-to-consumer prescription drug advertisements: major statement final rule](https://www.govinfo.gov/content/pkg/FR-2023-11-21/pdf/2023-25428.pdf)
- [Foley Hoag, FDA proposes to eliminate adequate provision](https://www.foleyhoag.com/news-and-insights/publications/alerts-and-updates/2026/july/fda-proposes-to-eliminate-adequate-provision-for-broadcast-prescription-drug-advertising/)
- [AbbVie (SEC), AbbVie Form 10-K 2025](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm)
- [PhRMA, Biopharmaceutical investment milestone](https://phrma.org/blog/icymi-biopharmaceutical-companies-in-america-hit-new-investment-milestone)
- [RELX, RELX results 2025](https://www.relx.com/~/media/Files/R/RELX-Group/documents/press-releases/2026/results-2025-pressrelease.pdf)
- [Wolters Kluwer, Wolters Kluwer 2025 full-year results](https://assets.contenthub.wolterskluwer.com/api/public/content/3118646-2026-02-25-wolters-kluwer-2025-full-year-results-7391945524?v=2c966da9)
- [Primal Pictures, Primal Pictures about](https://primalpictures.com/about/)
- [BioDigital, BioDigital about](https://www.biodigital.com/about)
- [Nucleus Medical Media, Nucleus Medical Media who we are](https://www.nucleusmedicalmedia.com/who-we-are)
- [Graphite Capital, Graphite Capital sells Random42 to The Lockwood Group](https://www.graphitecapital.com/news/graphite-capital-sells-random42-to-the-lockwood-group)
- [AAMC, US medical schools enroll record number of students in 2025](https://www.aamc.org/news/us-medical-schools-enroll-record-number-students-2025)
- [WFME and Intealth, World Directory of Medical Schools](https://www.wdoms.org/about/)
- [Association of Medical Illustrators, Graduate programs in medical illustration](https://ami.org/medical-illustration/enter-the-profession/education/graduate-programs/)
- [US Bureau of Labor Statistics, Special effects artists and animators](https://www.bls.gov/ooh/arts-and-design/multimedia-artists-and-animators.htm)
- [Apple, Apple Vision Pro health apps](https://www.apple.com/newsroom/2024/03/apple-vision-pro-unlocks-new-opportunities-for-health-app-developers/)
- [Adobe, Creative Cloud individual plan changes](https://helpx.adobe.com/account/individual/subscriptions-and-plans/plan-types-and-eligibility/changes-to-individual-plan.html)
- [Autodesk, Maya vs Maya Creative vs Maya Indie](https://blogs.autodesk.com/media-and-entertainment/2026/10/26/autodesk-maya-vs-maya-creative-vs-maya-indie-which-one-is-best-for-you/)
- [Epic Games, Unreal Engine licensing](https://www.unrealengine.com/license)
- [Google, Generative media models at I/O 2025](https://blog.google/innovation-and-ai/products/generative-media-models-io-2025/)
- [Google, Veo 3 and Veo 3 Fast new pricing](https://developers.googleblog.com/veo-3-and-veo-3-fast-new-pricing-new-configurations-and-better-resolution/)
- [OpenAI, Sora 2 is here](https://openai.com/index/sora-2/)
- [OpenAI, Sora discontinuation notice](https://help.openai.com/en/articles/20001152)
- [EUR-Lex, Directive 2001/83/EC](https://eur-lex.europa.eu/eli/dir/2001/83/oj)
- [EUR-Lex, Regulation (EU) 2024/1689 (AI Act)](https://eur-lex.europa.eu/eli/reg/2024/1689/oj)

## How to cite

Douglas Insights, "Medical Animation Market", DI-HC-10878, updated 2026-11-06, https://www.douglasinsights.com/medical-animation-market/